Company Profile and Highlights

Private clinical company operating in San Francisco and Calgary

- **Global lead** in developing BETi epigenetic combination cancer therapies that address resistance to commercially significant drugs
  - + PARPi
  - + AR antagonists
  - + Immune checkpoint Mabs
  - + MEKi

These specific oncology targets represent the hottest advancement areas in cancer fighting today!
Company Profile and Highlights

Private clinical company operating in San Francisco and Calgary

- **Global lead** in developing BETi epigenetic combination cancer therapies that address resistance to commercially significant drugs
  - + PARPi
  - + AR antagonists
  - + Immune checkpoint Mabs
  - + MEKi

- **Registration enabling studies in process for 2021**

These specific oncology targets represent the hottest advancement areas in cancer fighting today!
Private clinical company operating in San Francisco and Calgary

- **Global lead** in developing BETi epigenetic combination cancer therapies that address resistance to commercially significant drugs
  - + PARPi
  - + AR antagonists
  - + Immune checkpoint Mabs
  - + MEKi

These specific oncology targets represent the hottest advancement areas in cancer fighting today!

- **Registration enabling studies in process for 2021**
  - ZEN-3694 + talazoparib (not exclusive PARP) in TNBC (biomarker)
Private clinical company operating in San Francisco and Calgary

- **Global lead** in developing BETi epigenetic combination cancer therapies that address resistance to commercially significant drugs
  - + PARPi
  - + AR antagonists
  - + Immune checkpoint Mabs
  - + MEKi

- **Registration enabling studies in process for 2021**
  - ZEN-3694 + talazoparib (not exclusive PARP) in TNBC (biomarker)
  - ZEN-3694 + enzalutamide in mCRPC patients with poor response to abiraterone

These specific oncology targets represent the hottest advancement areas in cancer fighting today!
Company Profile and Highlights

Private clinical company operating in San Francisco and Calgary

• **Global lead** in developing BETi epigenetic combination cancer therapies that address resistance to commercially significant drugs
  - + PARPi
  - + AR antagonists
  - + Immune checkpoint Mabs
  - + MEKi

  *These specific oncology targets represent the hottest advancement areas in cancer fighting today!*

• **Registration enabling studies in process for 2021**
  - ZEN-3694 + talazoparib (not exclusive PARP) in TNBC (biomarker)
  - ZEN-3694 + enzalutamide in mCRPC patients with poor response to abiraterone

• **National Cancer Institute** clinical collaboration for developing multiple BETi combination therapies in molecularly defined cancers
Company Profile and Highlights

Private clinical company operating in San Francisco and Calgary

- **Global lead** in developing BETi epigenetic combination cancer therapies that address resistance to commercially significant drugs
  - + PARPi
  - + AR antagonists
  - + Immune checkpoint Mabs
  - + MEKi

- **Registration enabling studies in process for 2021**
  - ZEN-3694 + talazoparib (not exclusive PARP) in TNBC (biomarker)
  - ZEN-3694 + enzalutamide in mCRPC patients with poor response to abiraterone

- **National Cancer Institute** clinical collaboration for developing multiple BETi combination therapies in molecularly defined cancers

- Strong partnerships with multinational pharmaceutical companies
Zenith’s Clinical Pipeline (no assigned rights except China)

### ZEN-3694 BETi Programs

**Pre-Clin** | **Phase 1** | **Phase 2** | **Pivotal**
--- | --- | --- | ---
AR independent mCRPC - Prostate (+ enzalutamide) | | | Newsoara (China)
TNBC (+ talazoparib) - Breast | | | Pfizer
AR Independent CRPC - Prostate (+ Keytruda + enzalutamide) | | | UCSF, Merck
Immune-oncology Combinations (+ PD-1 Mab + anti-CTLA4 Mab) | | | NIH, Bristol Myers Squibb
Ovarian, TNBC, Melanoma | | | Dana-Farber Cancer Institute, Cleveland Clinic
Other Combinations (+ PARPi, +MEKi, CDK4/6i, chemo) | | | MD Anderson Cancer Center
HR+ breast, CRC, Ovarian, CRPC, NmC
Published Prostate Trial Data

Primary resistance to abiraterone data is advancing to Phase 2b/3 in China first

Clinical data and AI platform show that both ZEN-3694 and enzalutamide required for durable PSA response.

Three patients with significant and durable PSA response, after poor response to abiraterone.

Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform

Allan J. Portuck, Dong-Keun Lee, Theodore Kee, Peter Wang, Sanjay Lakhotia, Michael H. Silverman, Colleen Mathis, Alexandra Drakaki, Ari S. Beldegrun, Chih-Ming Ho, and Dean Ho
Combining talazoparib with ZEN003694 in people with triple-negative breast cancer without inherited faulty BRCA1/2 genes

Date of summary: December 2020
Study number: NCT03901469 | Study start date: June 2019 | Estimated study end date: January 2022

The full title of this abstract is: A phase 1b/2 study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations
Who took part in this study?

Who is taking part in this study?

- 15 people with TNBC*
  - were HER2- and did not have inherited faulty BRCA1/2 genes
  - were not suited for hormone therapy or HER2- directed therapy
  - had received 1 or more types of chemotherapy for metastatic breast cancer

* People could have low levels of estrogen and/or progesterone receptors on their tumors but their cancer was not likely to respond to hormone therapy.
People received talazoparib and ZEN003694 by mouth until their cancer got worse or they had to stop treatment due to developing side effects.

**Talazoparib** + **ZEN003694**

**Group 1**
- 1 mg
- 48 mg

**Group 2**
- 0.75 mg
- 48 mg

**Group 3**
- 1 mg
- 36 mg

*Slide material and content compiled by Pfizer Inc.*
Talazoparib and ZEN003694 reduced levels of important genes and showed activity against cancer

For more than 8 hours after the drugs were taken, CCR1, IL1RN, and IL8 genes, which are dependent on BET, were reduced by more than half.

Doctors reported that in 6 out of 10 people, their tumors shrank or did not grow.

Based on side effects and effectiveness the recommended doses for the next studies were:

Talazoparib 0.75 mg + ZEN003694 48 mg
What were the main conclusions reported by the researchers?

- This small study in people with metastatic TNBC without inherited faulty BRCA genes provided early evidence that combining talazoparib with ZEN003694 may stop tumors from growing. More people will take part in the second part of this ongoing study.

- The amount of talazoparib plus ZEN003694 in the blood increased as the dose of each study drug was increased.

- With the combination of drugs, the most common side effect was low levels of platelets in the blood (called thrombocytopenia).
  - Reducing the dose of talazoparib plus ZEN003694 or temporarily stopping treatment helped manage this side effect. These dose reductions or temporary stops in treatment did not seem to affect the activity of these drugs against tumors.

Who sponsored this study?

Zenith Epigenetics Ltd.
44 Montgomery Street, Suite 4010, San Francisco, CA 94104
Phone (United States): +1 587-390-7865

Pfizer Inc.
235 East 42nd Street NY, NY 10017
Phone (United States): +1 212-733-2323

The sponsors would like to thank all of the people who took part in this study.
TBNC Program Highlights Significant Breakthrough in PARP Combo

Legend:
- PD: Progressive Disease
- PR: Partial Response
- ORR: Overall Response Rate (Complete Response + Partial Response)
- CBR: Clinical Benefit Rate (ORR + Stable Disease)

### ZEN-3694 + Talazoparib

<table>
<thead>
<tr>
<th></th>
<th>Biomarker selected (N=17)</th>
<th>ZEN-3694+Talazoparib Biomarker unselected (N=13)</th>
<th>All patients (N=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ORR %</strong></td>
<td>41%</td>
<td>8%</td>
<td>27%</td>
</tr>
<tr>
<td><strong>CBR (&gt; 4 mo) %</strong></td>
<td>59%</td>
<td>29%</td>
<td>45%</td>
</tr>
<tr>
<td><strong>CBR (&gt; 6 mo) %</strong></td>
<td>56%</td>
<td>8%</td>
<td>43%</td>
</tr>
</tbody>
</table>

%Change in Target Lesions

- **PD= 20% increase**
- **PR= 30% decrease**

Slide material and content compiled by Pfizer Inc.
TNBC Program Highlights Significant Breakthrough in PARP Combo

Legend:
- **PD**: Progressive Disease
- **PR**: Partial Response
- **ORR**: Overall Response Rate (Complete Response + Partial Response)
- **CBR**: Clinical Benefit Rate (ORR + Stable Disease)

<table>
<thead>
<tr>
<th>TRODELVY (Marketed by Gilead)</th>
<th>ZEN-3694 + Talazoparib</th>
<th>ZEN-3694 + Talazoparib</th>
<th>All patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Biomarker selected (N=17)</td>
<td>Biomarker unselected (N=13)</td>
<td>(N=30)</td>
</tr>
<tr>
<td><strong>ORR %</strong></td>
<td>41%</td>
<td>8%</td>
<td>27%</td>
</tr>
<tr>
<td><strong>CBR (&gt; 4 mo) %</strong></td>
<td>59%</td>
<td>29%</td>
<td>45%</td>
</tr>
<tr>
<td><strong>CBR (&gt; 6 mo) %</strong></td>
<td>56%</td>
<td>8%</td>
<td>43%</td>
</tr>
</tbody>
</table>
2020 Milestones Leading to Major Collaborations

- Spun out from Resverlogix Corp. 2013

- Ph2 Collaboration with Pfizer continues (TNBC) – moves towards efficacy stage

- NCI CRADA announced. Clinical collaboration for multiple oncology clinical trials with different combination agents

- Bristol Myers Squibb
  - First NCI CRADA study announced, NCI co-collaborating with Zenith and Bristol Myers Squibb (BMS) investigating ZEN-3694 with nivolumab and ipilimumab – in resistant ovarian cancer

- Received US$5M milestone payment from Newsoara (China region partnership) upon successful completion of Ph2 mCRPC US study in combination with enzalutamide

- Regulatory advancement in China for ph2b/3 mCRPC study – paving way for worldwide development

- UCSF-initiated clinical study using Keytruda, Enzalutamide and ZEN-3694 for mCRPC – study design published

- Ph2 Collaboration with Pfizer proceeds to final efficacy stage of the Ph2 TNBC trial – advancing towards future registration